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Abstract
Background: Spinal manipulative therapy (SMT) includes biomechanical parameters that vary between clinicians,
but for which the influence on the therapy clinical effects is unknown. This parallel-randomized controlled trial
aimed to investigate the effect of SMT biomechanical parameters on the outcomes of participants with chronic
thoracic pain (CTP) following three treatment sessions (follow-up at one week).
Methods: Adults reporting CTP (pain within the evaluated region [T6 to T8] for ≥3 months) were asked to
participate in a four-session trial. At the first session, participants were randomly assigned to one of three
experimental groups (different SMT doses) or the control group (no SMT). During the first three sessions, one SMT
was executed at T7 for the experimental groups, while a 5-min rest was provided to the control group. SMT were
delivered through an apparatus using a servo-controlled linear actuator motor and doses consisted of peak forces,
impulse durations, and rates of force application set at 135 N, 125 ms and 920 N/s (group 1), at 250 N, 125 ms and
1840 N/s (group 2), and at 250 N, 250 ms, 920 N/s (group 3). Disability and pain intensity were evaluated at each
session (primary outcomes). Spinal stiffness was assessed before-and-after each SMT/rest and at follow-up.
Tenderness and muscle activity were evaluated during each spinal stiffness trial. Improvement was evaluated at
follow-up. Differences in outcomes between groups and sessions were evaluated as well as factors associated with
clinical improvement.
Results: Eighty-one participants were recruited and 17, 20, 20 participants of the three experimental groups and 18
of the control group completed the protocol. In exception of higher pain intensity at baseline in the control group,
no between-group differences were found for any of the outcomes. A decrease in pain intensity, disability, spinal
stiffness, and tenderness during spinal stiffness were observed (p-values< 0.05). At follow-up, 24% of participants
were classified as ‘improved’. Predictors of improvement were a greater decrease in pain intensity and in
tenderness (p-values< 0.05).
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Conclusions: In an experimental setting, the delivery of a SMT does not lead to significantly different outcomes in
participants with CTP than a control condition (spinal stiffness assessment). Studies are still required to explore the
mechanisms underlying SMT effects.
Trial registration: ClinicalTrials.gov NCT03063177, registered 24 February 2017).
Keywords: Spinal stiffness, Thoracic spine, Chronic pain, Electromyography, Spinal manipulation, Manual therapy,
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Background
Back pain is highly prevalent in the general population and
can lead to important individual and socioeconomic conse-
quences [1]. The annual prevalence of low back pain (LBP)
and middle back pain is respectively estimated at around 43
and 35% [2]. Complementary and alternative medicine is
widely used by patients with back pain, with about 75% of
patients consulting either in chiropractic, physical therapy
or osteopathy [3]. Spinal manipulative therapy (SMT) and
spinal mobilization constitute treatment options commonly
offered by these clinicians and are now recommended in
several clinical practice guidelines for the management of
spinal pain [4–6]. Overall, these therapies are characterized
by the delivery of a force using specific parameters of angu-
lation, amplitude and speed to an intervertebral articulation,
which results in specific biomechanical and/or neurophysio-
logical effects [7]. Although SMT targets an intervertebral
joint, the manual force is transmitted to the contiguous ar-
ticulations and surrounding soft tissues. Previous studies
have shown the presence of a dose-response relationship be-
tween the therapy characteristics and individuals’ neurome-
chanical responses (i.e. the targeted vertebra displacement,
the relative displacement with its adjacent vertebrae and the
response amplitude of surrounding muscles) [8–11]. Specif-
ically, the muscle response amplitude increases with the in-
crease in peak force [10], while it decreases when preload
forces [9] and the impulse duration increase [8]. Regarding
the absolute movement of the contacted vertebra, it in-
creases with increasing peak forces [11] and with the de-
crease in the preload force [9]. Although SMT yields
neuromechanical responses that are believed to be linked to
clinical effects, the effect of different SMT doses have been
investigated in only one previous randomized controlled
trial [12] highlighting the need for further investigations.
Nonspecific back pain regroups heterogenous patients
that might not respond similarly to a given treatment. The
identification of patient profiles that could help guide treat-
ment options is now recognized as a key issue in back pain
research [13]. Recently, monitoring of spinal stiffness mea-
sured using a mechanical device has shown to effectively
identify patients with LBP who are more susceptible to im-
prove following few SMT sessions [14, 15]. Specifically,
Fritz et al. (2011) showed that a decrease in lumbar spinal
stiffness following the first treatment is an independent
predictor of improved disability at one week after two ses-
sions of lumbopelvic SMT [14]. Using a similar protocol,
Wong et al. (2015) observed, in participants with acute
and chronic LBP, a significant decrease in L3 spinal stiff-
ness following the first treatment, but only among those
who reported a clinically significant improvement in dis-
ability following the two treatments [15]. None of these
studies have recorded the SMT dose delivered by clini-
cians nor attempted to standardize the treatment using a
mechanical device.
It is therefore unknown if triggering neuromechanical
responses of greater magnitude influences SMT clinical,
such as pain and disability, and biomechanical, such as
spinal stiffness, outcomes in participants with spinal
pain. Identifying a dose optimizing these outcomes could
have important educational implications and ultimately
lead to the improvement of patient care. The overall goal
of this study was therefore to increase the understanding
of the mechanisms underlying the clinical effects of
SMT through an apparatus using a servo-controlled lin-
ear actuator motor. Within an experimental paradigm, a
modified parallel-randomized controlled trial was de-
signed to investigate the effect of different SMT doses
(i.e. including different peak forces and rates of force ap-
plication) on the clinical and biomechanical outcomes of
participants with chronic thoracic pain following three
treatment sessions (follow-up one week after the last
treatment). It was hypothesized that the SMT peak force
and rate of force application would influence the pri-
mary (pain intensity and disability) and secondary (spinal
stiffness, and tenderness and muscle activity during the
assessment of spinal stiffness) outcomes. It was also hy-
pothesized that participants receiving SMT would show
a greater improvement in the primary outcomes than
those not receiving SMT. Moreover, since this study was
exploratory, an analysis of factors associated with clinical
improvement was also conducted.
Methods
Trial design
This controlled trial used a parallel design where partici-
pants were allocated using a 1:1 ratio between the four
groups (three experimental groups and one control group).
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The trial is reported according to the CONSORT 2010
statement [16].
Participants
Adults with chronic thoracic pain were recruited through
advertisements in the Trois-Rivières (Québec, Canada)
local newspaper and social media. Inclusion and exclusion
criteria are presented in Table 1.
Procedures and intervention
Participants took part in four experimental sessions over a
period of 2 to 3 weeks. The first three sessions, that were
scheduled two to four days apart, were labeled as the
treatment sessions, while the fourth session constituted
the follow-up and occurred six to eight days following the
last treatment session. A complete description of each
procedure is presented below but, briefly, participants first
completed a series of questionnaire and were evaluated
for inclusion and exclusion criteria (including a physical
examination). Following a demonstration of the SMT and
spinal stiffness assessment procedures using the apparatus
and explanation of its main safety features, participants
laid face down on a treatment table (Techniques Tables
Ltd., model TT5001029, Ontario, Canada). Identification
of T6, T7 and T8 spinous processes and of T7 transverse
processes was then performed by the investigator (IP)
using a standardized procedure [18, 19] and surface elec-
tromyography (sEMG) electrodes were positioned over
the thoracic erector spinae just below and over the T7
transverse processes area. A sEMG normalization trial
was completed, followed by the assessment of spinal stiff-
ness and SMT (experimental groups) or rest (control
group) procedure. Spinal stiffness was reassessed immedi-
ately following SMT/rest. These procedures were repli-
cated during the second and third sessions, while the
follow-up only included the completion of clinical ques-
tionnaires and the assessment of spinal stiffness. Figure 1
shows the experimental setup including the sEMG elec-
trodes localization and contact areas for the assessment of
spinal stiffness and SMT delivery.
Questionnaires at baseline
At the beginning of the first session, participants’ sex, age,
weight and height, in addition to information regarding
pain patterns (constant pain about every other day; or re-
current pain less than every other day), sick leave due to
thoracic pain and mean pain intensity in the past three
months (0–100 visual analog scale with 0 - no pain and
100 – extreme pain; VAS [20]) were gathered. Actual pain
intensity (VAS), disability (Quebec Back Pain Disability
Questionnaire – QBPDQ, /100) [21], Kinesiophobia
(Tampa Scale of Kinesiophobia – TSK, score > 40/68 sug-
gesting kinesiophobia) [22] and risk of symptoms persist-
ence (STarT Back Screening Tool – SBST, score ≥ 5/9
suggesting physical findings accompanied or not by psy-
chosocial barriers to recovery) [23] were also evaluated.
Additionally, participants were asked to evaluate their ex-
pectation towards their improvement at the fourth ses-
sion. Participants were considered presenting a positive
expectation if they expected that their condition “will im-
prove” or a negative expectation if they expected that their
condition “will deteriorate” or “will not change”.
Spinal manipulative therapy procedure
The intervention consisted of a single SMT delivered
through an apparatus using a servo-controlled linear ac-
tuator motor (Linear Motor Series P01-48 × 360, LinMot
Inc., Zurich, Switzerland) [24]. The indenter device con-
sisted of a twin-tip padded rod (θ tip = 10 mm; distance
between the center of the tips = 56mm) contacting the
skin overlying T7 transverse processes (Fig. 2). This
spinal level was targeted for all participants considering
technical limitation with the apparatus and the lack of a
current gold standard to determine a spinal level that
would benefit the most of a SMT. However, participants
had to report pain in the targeted area (T6-T8) to be in-
cluded in the study (see Table 1). SMT were character-
ized by a preload force of 20 N maintained during 1 s
followed by the application of a specific force. The mag-
nitude of the applied force, the impulse duration and the
rate of the force application varied between groups (ex-
perimental groups) and were within the range of doses
Table 1 Inclusion and exclusion criteria
Criteria Participants with chronic thoracic pain
Inclusion criteria ▪ 18 and 60 years old.
▪ Thoracic pain * for at least 3 months (constant or recurrent).
▪ Pain within T6 to T8 region indicated on the pain diagram and/or during physical examination at the start of the first session.
▪ Pain intensity at the start of the first session ≥5/100.
Exclusion criteria ▪ Having a history of thoracic surgery or fracture.
▪ Diagnosed with a non-spine-related condition that might refers pain to the chest wall (e.g. heart, lung or oesophagus conditions).
▪ Diagnosed or suspected with one of the following conditions: spine-related inflammatory arthritis, aorta aneurism, advanced
osteoporosis, neuromuscular disease, myelopathy, malignant tumors, uncontrolled hypertension, radiculopathy, neurologic deficit,
thoracic herniated disc, current infection, thoracic scoliosis (Cobb’s angle > 20°).
▪ Being a pregnant woman.
* Thoracic pain was defined as pain in the region bounded superiorly by the T1 spinous process, inferiorly by the T12 spinous process and laterally by the lateral
margins of the erector spinae muscles [17]
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used by manual therapists [25]. The Dose 1 group con-
sisted of a peak force of 135 N applied in 125 ms and
resulting in a rate of 920 N/s. These parameters were re-
spectively set at 250 N, 125 ms and 1840 N/s for the
Dose 2 group. The Dose 3 group consisted of the same
peak force as the second group (250 N) applied in 250
ms and resulting in the same rate of force application as
the Dose 1 group (920 N/s). Participants of the fourth
group (the control group) rested quietly for 5 min in-
stead of receiving a SMT. For each SMT, the preload
force (N), peak force (N), impulse duration (ms), rate of
force application (N/s), velocity (mm/s) and indenter
displacement during the impulse phase were computed
using the mechanical device displacement (mm), force
(N) and time (ms) data recorded at 204.8 Hz.
Spinal stiffness procedure
Immediately before and after the intervention (SMT/
rest), spinal stiffness was assessed four times at T6, T7
and T8 spinous processes by the same apparatus used to
deliver the SMT. The measurement of spinal stiffness
using this device has been shown to be reliable at T6, T7
and T8 [26]. The indenter head (18 mm × 25mm) was
covered by high-density silicone padding and was posi-
tioned over the targeted spinous process (Fig. 2). A
randomization scheme [27] was used to determine in
which order the spinal levels would be assessed for each
participant. For every spinal stiffness trial, the investiga-
tor instructed the participant to inhale, exhale, and then
hold his breath during measurement (~ 5 s). During ex-
halations, the linear motor displaced the indenter until
applying a 5 N load on the spinous process. While the
participant held his breath, a total load of 45 N was
gradually applied using an 18 N/s rate of the force appli-
cation. This load was maintained for 1 s before being
withdrawn. LinMot-Talk 5.1 (LinMot Inc., Elkhorn, Wis-
consin, USA) was used to sample the applied force and
resulting indenter displacement at a frequency of 135
Hz. After each trial, participants rated their tenderness
during the procedure (0–100 VAS) and the sEMG activ-
ity was recorded during each trial.
sEMG procedure
At the beginning of each session, four sEMG electrodes
were positioned bilaterally at approximately 2 cm from
the spine (over the thoracic erector spinae muscle belly)
just above and below the T7 transverse processes. To de-
crease skin impedance, the skin was shaved, gently
abraded with fine-grade sandpaper (Red Dot Trace Prep,
3M; St. Paul, MN, USA) and cleaned with alcohol
swabs. sEMG data were recorded at 2000 Hz using
Trigno™ Wireless EMG sensors (Delsys Inc., Natick,
Massachusetts, USA). Following instrumentation, partic-
ipants were asked to perform a normalization trial. This
Fig. 1 Experimental setup. sEMG electrodes, contact areas during
the spinal manipulative therapy (T7 transverse processes; circles) and
contact areas during spinal stiffness assessment (T6, T7 and T8
spinous processes; triangles) are visualized
Fig. 2 The mechanical device used to deliver the spinal manipulative
therapy and to assess spinal stiffness. A twin tip was used during spinal
manipulative therapy delivery, while a single tip was used during the
assessment of spinal stiffness
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trial consisted in maintaining, without support, the
upper trunk in line with the lower body for 5 s. sEMG
was recorded during each measurement of spinal stiff-
ness as well as during the impulse phase of each SMT.
Outcomes
The primary outcomes of this study were pain intensity
(VAS) and disability (Quebec Back Pain Disability Ques-
tionnaire - QBPDQ), while secondary outcomes were
spinal stiffness and both muscle activity and tenderness
during the assessment of this parameter. Time points at
which outcomes were evaluated are presented in Table 2.
The outcome for the exploratory analysis only included
the subjective improvement (“improved” or “not im-
proved”) at the follow-up. Indeed, at follow-up, partici-
pants completed a subjective overall improvement scale
(7-point Likert scale: strongly improved; moderately im-
proved; slightly improved; no change; slightly deterio-
rated; moderately deteriorated; or strongly deteriorated)
[28]. This outcome was further dichotomized in “im-
proved” (moderately or strongly improved) or “not im-
proved” (slightly improved to strongly deteriorated). The
outcomes were not modified following the start of the
recruitment process and were evaluated by the principal
investigator (IP).
Sample size
The required sample size was estimated using G*Power
software (G*Power 3.1) based on the results of Haas et
al. (2014) that showed an average decrease in pain inten-
sity of 17.70% (SD = 17.35%) in participants with low
back pain following 6 weeks of manual therapy [29]. A
minimum sample size of 13 participants was determined
to detect a statistically significant difference with a
power of 0.80, effects size of 0.5 and an alpha value of
0.05. Considering the attrition risk and the comparisons
between four groups, a sample size between 15 and 25
participants per group was targeted.
Randomization
One randomization scheme for males and one for fe-
males were generated using an online software [27] by
an independent investigator. This investigator subse-
quently wrote each allocation (either one of the three ex-
perimental groups or the control group) in a sealed
envelope identified with the participant’s sex (male or fe-
male) and a sequential number (1, 2, 3 …). Once a par-
ticipant provided informed consent, the lead investigator
(IP) opened the following envelope of the males’ or fe-
males’ pile.
Blinding
Due to the nature of the intervention, the investigator
(IP) and the participants of the control group were not
blinded, while participants of the experimental groups
were blinded to the specific SMT dose (i.e. the peak
force and rate of force application) they received.
Data analysis
Spinal stiffness calculation
To calculate spinal stiffness coefficients, a MATLAB
script was developed. Terminal and global spinal stiff-
ness coefficients were calculated using the force and dis-
placement data recorded during each spinal stiffness
trial. As previously suggested [30], the first trial of each
series of four measurements was excluded. The spinal
stiffness value obtained for the second, third and fourth
trials were therefore averaged to obtain one terminal
and global coefficient for each series of measurement.
The terminal coefficient was defined as the ratio of the
load divided by the displacement between 10 and 45 N,
while the global coefficient was defined as the slope of
Table 2 Primary and secondary outcomes evaluated, and time points used for analyses
Outcome Session 1 Session 2 Session 3 Session 4 (follow-up)
Primary outcomes
Pain intensity (VAS) at the session beginning X X X X
Back disability (QBPDQ) at the session beginning X X X X
Secondary outcomes
Spinal stiffness at T6, T7 and T8 (N/mm) Before SMT/rest X
Muscle activity during spinal stiffness at T6, T7
and T8 (nRMS)
During spinal stiffness procedure before SMT/rest X
Tenderness during spinal stiffness at T6, T7 and
T8 (VAS)
During spinal stiffness procedure before SMT/rest X
Outcome for the exploratory analysis
Subjective improvement X
VAS Visual analog scale (0–100); QBPDQ Quebec Back Pain Disability Questionnaire (0–100 score); nRMS normalized root mean square (i.e. amplitude of the
muscle activity)
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the straight-line best fitting the data over the same load
interval.
sEMG data processing
sEMG signals were processed using a custom MATLAB
(MathWorks®, Natick, Massachusetts, USA) script. Bipo-
lar sEMG data acquired during normalization trials were
first digitally band pass filtered using a 40 Hz low cut-off
frequency to filter the electrocardiogram signal contam-
inating the sEMG signal and a 400 Hz high cut-off fre-
quency (2nd order Butterworth filter). The root mean
square (RMS) value was then computed for each elec-
trode during a 2 s time-window, during which the signal
was visually stable.
To assess muscle activity during spinal stiffness trials,
the sEMG signals were submitted to the same filtering
than sEMG signals acquired during the normalization
trial. The RMS value was then computed for each elec-
trode between 10 and 45 N application and was normal-
ized (later referred to as nRMS) by dividing it by the
respective RMS value obtained during the normalization
trial. The average value from the four electrodes was
used for subsequent analyzes. The muscle response
amplitude during the impulse phase of each SMT was
similarly computed.
Statistical analysis
Baseline descriptive and comparative analysis
Mean (with SD) or median (with IQR =Q3-Q1) was
computed for the demographic characteristics and clin-
ical questionnaire scores at baseline as well as for spinal
stiffness (T6, T7 and T8), muscle activity during spinal
stiffness assessment and tenderness during spinal stiffness
assessments. Between-group differences were tested using
either analysis of variances (ANOVAs) or Kruskal-Wallis
tests (for non-parametric data). The neuromechanical re-
sponses (displacement and muscle activity) recorded dur-
ing the first session SMT were also compared between the
three experimental groups. The number of participants
initially presenting a positive expectation and of those pre-
senting a negative expectation towards their improvement
was calculated for each group. Statistics were computed
using SPSS Statistics 21 (IBM®, Armonk, New York, USA)
and statistical significance was set at p ≤ 0.05.
Primary outcomes analysis
Since pain intensity (VAS) and disability (QBODQ) were
non-normally distributed, they were respectively trans-
formed using the cubic root (VAStransf ) and the square
root (QBPDQtransf ) to restore quasi-normality. Repeated
measures ANOVAs was computed to evaluate if pain
intensity (VAStransf ) and disability (QBPDQtransf ) at the
session beginning differed between sessions and groups,
and if an interaction between these variables was
present. The presence of a monotonic trend of improve-
ment was determined by computing E 2 statistics [31]
and Tukey post-hoc tests were computed for significant
effects/interactions.
Secondary outcomes analysis
Spinal stiffness (terminal and global coefficients), and
tenderness (VAS) and muscle activity (nRMS) during the
assessment of spinal stiffness were identified as the sec-
ondary outcomes of this study. Each coefficient of spinal
stiffness was submitted to a 4 × 4 × 3 mixed-model
ANOVAs with Tukey post-hoc tests to evaluate if the
parameter differed between groups, sessions and spinal
levels as well as the presence of interactions between
these variables. Since tenderness and muscle activity
could not be transformed to meet the distribution re-
quirements of ANOVA, between-group differences were
assessed on changes in these variables between the first
and fourth sessions using Kruskal-Wallis nonparametric
procedure. Moreover, regardless of the group, differences
in these variables between the first assessment (pre
SMT/rest at the first session) and follow-up (fourth ses-
sion) were assessed using Wilcoxon Matched-Pairs test.
Exploratory analysis of factors associated with clinical
improvement
To conduct the exploratory analysis, participants were
divided between those “improved” and “not improved”
at follow-up. A logistic regression was computed to ex-
plore the role of the clinical and biomechanical out-
comes in the prediction of “improved” participants. First,
differences in the demographic (age, weight, height and
BMI), baseline clinical (mean pain intensity in the past
3 months, pain intensity, disability, TSK score, SBST
score, and tenderness during spinal stiffness) and bio-
mechanical (muscle activity during spinal stiffness and
spinal stiffness) variables were determined between “im-
proved” and “not improved” participants using t-test for
independent samples (parametric data) or Mann-Whitney
U test (nonparametric data). Other potential variables to
include in the logistic regression were determined by com-
puting these tests between “improved” and “not improved”
participants on the ‘slopes of change’ in VAStransf,
QBPDQtransf, global and terminal spinal stiffness, and ten-
derness and muscle activity during T6 to T8 spinal stiff-
ness assessment. For each variable, the ‘slope of change’
was calculated between values of the first two sessions and
between values of all sessions. The ‘slope of change’ of a
specific variable was defined by the coefficient of the
straight-line best fitting the values over time for a partici-
pant (e.g. pain intensity at session 1, 2, 3 and 4). ‘Slopes of
change’ in tenderness, muscle activity and spinal stiffness
were also computed between values of before and after
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the first SMT/rest. All variables presenting significant dif-
ference between “improved” and “not improved” partici-
pants were included in the logistic regression model.
Besides the logistic regression, the positive predictive value
of an initial positive expectation and the negative predict-
ive value of an initial negative expectation were computed




The recruitment started on May 1st, 2017 and the last
follow-up occurred on December 22nd,2017. The trial
ended considering that the number of participants
within each group laid within the range estimated (15 to
25 per group).
Participant flow
A total of 81 participants were randomly assigned in ei-
ther one of the three experimental groups (Dose 1
group = 21 participants; Dose 2 group = 22 participants;
Dose 3 group = 21 participants) or the control group (18
participants). All participants received the intended
intervention. Data of 18 participants of the control
group, 17 of the Dose 1 group, 19 of the Dose 2 group
and 20 of the Dose 3 group were included for analysis.
The experimental flow is shown in Fig. 3.
Baseline data
Baseline characteristics are reported in Table 3. Groups
were similar at baseline with the exception of pain inten-
sity: despite the randomization procedure, participants
in the control group presented significantly higher pain
intensity at baseline than participants in Dose 2 group
(p = 0.01). Initially, 65.0, 81.8, 85.7 and 56.0% of partici-
pants in Dose 1, Dose 2, Dose 3 and control groups re-
spectively presented a positive expectation towards their
improvement at the fourth session.
Comparison of the neuromechanical responses during
SMT between the three experimental groups revealed less
displacement in the Dose 1 group (11.82 ± 1.70mm) than in
the Dose 2 group (21.49 ± 1.69 mm; p < 0.001) and the
Dose 3 group (22.70 ± 1.70mm; p < 0.001): F2, 60 = 197.30,
p < 0.001, η2p = 0.87). Muscle activity during the impulse
phase was significantly greater in the Dose 2 group (me-
dian ± IQR = 0.46 ± 0.70) compared to the Dose 1 group
(0.17 ± 0.26; p= 0.01): H2 = 11.25, p= 0.003. Muscle activity
during the impulse phase in the Dose 3 group (0.43 ± 0.36)
was non-significantly different than the muscle activity in
Dose 1 (p = 0.10) and Dose 2 (p= 0.71) groups. These results
suggest that the SMT doses generated significantly different
neuromechanical responses (displacement and muscle activ-
ity). The average value of SMT biomechanical parameters
and resulting displacements and muscle activity received by
each experimental group may be visualized in the Fig. 4.
Results for the primary outcomes
Primary and secondary outcomes at each time point are
reported in the additional Table (see Additional file 1:
Table S1). The analysis revealed no significant between-
group differences in disability across the four sessions
(F3, 71 = 0.43, p = 0.73), but confirmed the presence of
higher pain intensity at baseline within the control
group compared to the Dose 2 group (F3, 71 = 3.61, p = 0.02,
η2p = 0.13). Both pain intensity and disability were
Fig. 3 Flow chart of the study. SMT: spinal manipulative therapy
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significantly different between sessions: F3, 213 = 18.92,
p < 0.001, η2p = 0.21 and F3, 71 = 0.43, p= 0.73 respectively. E
2
statistics confirmed the presence of a gradual improvement
across sessions, regardless of group allocation, in regards of
pain intensity (E 24,213 = 0.21, p < 0.01) and disability
( E 24,210 = 0.33, p < 0.01). Pain intensity decreased by an
average of − 11.70% (95%CI = − 15.37 to − 7.94) between
the first and the fourth session, while disability decreased
by an average of − 4.79% (95%CI = − 5.87 to − 3.70). Pain
intensity at baseline was also included as a covariable in a
repeated-measures ANCOVA for disability but it didn’t
impact the results (i.e. no between-group differences but
improvement across the sessions).
Results for the secondary outcomes
Analyses revealed no statistically significant difference in
any of the secondary outcomes (spinal stiffness, tenderness
and muscle activity during spinal stiffness) between the four
groups (all p values > 0.05). However, changes over time
were observed (including in the control group). Indeed,
spinal stiffness was similar at T6 between all sessions
(p values ≥ 0.05), while, at T7 and T8, spinal stiffness
at the first session was significantly higher than at the
other sessions (except between the first and third sessions
for T7 global stiffness) (p values < 0.05). The global stiff-
ness showed a mean decrease of − 0.01 (95%CI = − 0.20 to
0.17) N/mm at T6, − 0.25 (− 0.43 to − 0.07) N/mm at T7
and of − 0.32 (− 0.51 to − 0.13) N/mm at T8. These
changes were respectively − 0.04 (− 0.22 to 0.15), − 0.25
(− 0.43 to − 0.08) and − 0.33 (− 0.53 to − 0.14) N/mm
for the terminal stiffness. Moreover, a significant de-
crease in tenderness between the first and the fourth
session was observed at T6 (− 3.83, 95%CI = − 6.49 to
− 1.17; z = 3.18, p = 0.001), T7 (− 2.41, 95%CI = − 4.75
to − 0.08; z = 2.13, p = 0.03) and T8 (− 2.48, 95%CI =
− 4.65 to − 0.30; z = 2.40, p = 0.02). No significant
between-session differences were revealed for muscle







Control F3,77 or H3 value
and p value
Males: Females 6: 14 8: 14 8: 13 6: 12 –
Age (years) 41.50 (13.79) 37.45 (13.48) 37.19 (11.14) 35.83 (13.68) F = 0.57; p = 0.64
Weight (kg) 70.88 (12.66) 72.21 (18.80) 74.66 (18.90) 68.85 (13.15) F = 2.03; p = 0.12
Height (m) 1.65 (0.08) 1.67 (0.07) 1.68 (0.10) 1.68 (0.07) F = 0.69; p = 0.56
Body mass index (kg/m2) 26.12 (4.62) 28.91 (7.15) 26.09 (4.51) 24.48 (4.27) F = 2.43; p = 0.07
Average pain intensity in the past three months
(0–100, median, IQR)
30.00 (20.00) 27.50 (10.00) 30.00 (26.00) 50.00 (40.00) H = 7.51; p = 0.06
Pain intensity at the start of the first session
(0–100, median, IQR)
20.00 (10.00) 20.00 (15.00) 30.00 (29.97) 50.00 (44.00) H = 12.06, p = 0.01*
TSK score (/68) 30.45 (7.26) 31.64 (6.89) 31.71 (8.23) 33.39 (6.17) F = 0.53; p = 0.66
QBPDQ score (%, median, IQR) 9.00 (15.00) 16.31 (18.09) 12.92 (11.51) 12.50 (15.00) H = 1.47 p = 0.69
SBST score (/9, median, IQR) 2.00 (3.00) 2.00 (3.00) 3.00 (3.00) 3.50 (2.00) H = 6.73; p = 0.08
Global spinal stiffness at the first session before
SMT/rest (N/mm)
T6 8.02 (1.20) 7.49 (1.62) 7.70 (1.62) 8.14 (1.43) F = 0.81; p = 0.49
T7 7.96 (1.05) 7.38 (1.80) 7.72 (1.83) 8.03 (1.18) F = 0.75; p = 0.52
T8 7.73 (1.18) 7.39 (1.87) 7.62 (1.98) 7.80 (1.63) F = 0.23; p = 0.87
Terminal spinal stiffness at the first session before
SMT/rest (N/mm)
T6 8.06 (1.26) 7.50 (1.65) 7.73 (1.64) 8.20 (1.44) F = 0.88; p = 0.46
T7 7.98 (1.07) 7.41 (1.88) 7.75 (1.95) 8.06 (1.21) F = 0.69; p = 0.56
T8 7.77 (1.24) 7.39 (1.90) 7.64 (2.07) 7.86 (1.66) F = 0.27; p = 0.84
Tenderness during spinal stiffness assessment
(%, median, IQR)
T6 18.83 (22.50) 13.33 (23.33) 16.67 (18.67) 19.17 (23.33) H = 2.42; p = 0.49
T7 13.33 (24.33) 5.00 (16.33) 10.00 (20.00) 15.00 (16.33) H = 2.84; p = 0.42
T8 9.33 (19.33) 4.17 (21.00) 8.33 (16.67) 10.00 (18.33) H = 1.26; p = 0.74
Muscle response amplitude during spinal
stiffness assessment (nRMS, median, IQR)
T6 0.10 (0.09) 0.13 (0.11) 0.08 (0.15) 0.11 (0.10) H = 4.78; p = 0.19
T7 0.10 (0.06) 0.14 (0.13) 0.08 (0.06) 0.11 (0.11) H = 5.12; p = 0.16
T8 0.09 (0.05) 0.13 (0.13) 0.08 (0.04) 0.11 (0.09) H = 5.02; p = 0.17
Expectation (+: - or neutral) 13: 7 18: 4 18: 3 10: 8 –
Mean and standard deviation are reported unless otherwise indicated
Note: pain intensity and QBPDQ are de-transformed values
* Participants in the control group presented higher pain intensity at baseline than participants in the Dose 2 group
Abbreviation: IQR interquartile range, TSK Tampa Scale of Kinesiophobia, QBPDQ Quebec Back Pain Disability Questionnaire, SBST STarT Back
Screening Tool, SMT spinal manipulative therapy, nRMS normalized root mean square
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activity during spinal stiffness (p values at each
spinal level ≥ 0.05).
Results for the exploratory analysis
At the fourth session, a total of 18 participants were “im-
proved”, while 59 were “not improved”. Three (16%) partic-
ipants of the Dose 1 group, 7 (35%) of the Dose 2 group, 6
(30%) of the Dose 3 group and 2 (11%) of the control group
were classified as “improved”. No significant differences
were observed in the baseline characteristics between “im-
proved” and “not improved” participants (p values ≥0.05)
with the exception of the SBST score for which “improved”
participants showed higher scores than “not improved” par-
ticipants (U = 366.0, p = 0.047). “Improved” participants ini-
tially presented a median (IQR, range) SBST score of 4 (3,
1–6), while “not improved” participants presented a median
score of 3 (3, 0–8). Probabilities of being “improved” and
“not improved” when presenting a positive and a negative
expectation were respectively of 28.6% and 90.5%.
Analyses revealed greater ‘slopes of change’ (i.e. a greater
decrease across the four sessions or between the first two
sessions or between before and after the SMT/rest at the first
session) among “improved” participants in 6 variables: pain
intensity across the four sessions (U= 268.5, p= 0.002); T6
tenderness across the four sessions (U= 326.0, p= 0.03); T6
tenderness between the first two sessions (U = 276.0,
p= 0.002); T8 tenderness between the first two sessions (U
= 357.5, p= 0.04); T8 terminal stiffness between the first two
sessions (U = 359.0, p= 0.04); and T7 tenderness between
before and after the first SMT/rest (U = 355.0, p= 0.03).
These variables, as well as SBST score and initial expectation
(positive or negative), were entered in the logistic regression
to determine if these variables significantly associated with
being “improved” at the follow-up (Table 4). Overall associ-
ation/prediction success was 87.7% (96.4% for “not im-
proved” and 61.1% for “improved” participants): φ= 0.65,
χ2(1) = 30.61, p < 0.001. Overall, a greater decrease in pain
intensity across the four sessions (p= 0.01), a greater de-
crease in tenderness during T6 spinal stiffness assessment
between the first two sessions (p= 0.048), and a higher SBST
score (p= 0.07) were significant and almost significant pre-
dictors of “improved” participants (or significant variables
associated with being “improved”).
Harms
One participant within the Dose 1 group left due in-
creased back pain that subsided more than 72 h after the
first SMT.
Fig. 4 a Spinal manipulative therapy parameters, b Muscle activity (pale bars, median ± IQR) and indenter displacement (dark bars, mean ± SD)
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Discussion
This study failed to demonstrate an effect of SMT dose
(i.e. the peak force and the rate of force application) on
the clinical and biomechanical changes in participants
with chronic thoracic pain. Overall, a decrease in the
primary (pain intensity and disability) and secondary
(spinal stiffness and tenderness during spinal stiffness as-
sessment) outcomes were observed across the sessions
not only regardless of the therapy dose (groups 1 to 3),
but also in the group that did not receive any SMT (con-
trol group).
SMT dose and spine-related pain
Comparisons with previous studies remain limited. The
RCT published by Snodgrass et al. (2014) seems to be
the only other study comparing the effect of a manual
therapy (i.e. spinal mobilization) of different doses on
clinical and biomechanical outcomes in a clinical popu-
lation [12]. These authors evaluated the immediate and
the short-term (~ 4 days) change in pressure pain thresh-
old (main outcome) and neck disability, pain intensity,
spinal stiffness and range of motion (secondary out-
comes) following either a 90 N spinal mobilization, a 30
N spinal mobilization or a placebo (detuned laser) in
participants with chronic nonspecific neck pain. Their
results revealed no between-group difference on the pri-
mary outcome but, in contrast with the current study,
suggested a dose effect on neck pain intensity and spinal
stiffness. Indeed, the 90 N spinal mobilization group
showed, at short-term, greater decrease in pain intensity
than the 30 N spinal mobilization group and in spinal
stiffness than the placebo group. Authors concluded that
a specific dose of mobilization (force applied), appears
necessary to reduce spinal stiffness and potentially pain.
However, their results also revealed a non-statistically
significant change in pain intensity between the 90 N
spinal mobilization and the placebo groups, and in
spinal stiffness between the 90 N spinal mobilization and
the 30 N spinal mobilization groups. These results are
therefore more consistent with an absence of a strong
influence of SMT characteristics on this therapy effects
This might partly explain the lack of significant differ-
ence between the groups of the current study especially
considering that all participants (included the control
group) received light mobilization through the assess-
ment of spinal stiffness.
Besides the fact that the spinal stiffness procedure
could have resulted in a clinical improvement and thus
might have limited the possibility to detect
between-group differences, other reasons could explain
the absence of significant between-group differences in
the current study. First, although participants were asked
to be symptomatic at baseline, the severity of their clin-
ical status could be considered, in average, mild to mod-
erate which could have resulted in a floor effect
considering the limited window of improvement. This
also explains that the average change in pain intensity
(− 11.70%) and disability (− 4.79%) fell below the min-
imal clinically important difference (MCID) thresholds
which are respectively estimated to be 15% and 20%
[32]. Future studies should aim to recruit participants
presenting at least a moderate level of pain intensity and
disability to evaluate the effect of SMT doses in a more
clinically relevant population. Secondly, higher pain in-
tensity at baseline was observed in the control group,
these participants were, therefore, more susceptible to
improve due to the regression toward the mean
phenomenon which can have hidden a difference in the
clinical improvement between the control group and the
experimental groups. Third, it cannot be excluded that
the changes in the clinical outcomes reflect the natural
improvement of back pain which is known to constitute
a cyclic condition and has been reported to be independ-
ent of the intervention received [33]. Finally, the im-
provement might reflect that the contextual factors of a
treatment are more important of the treatment modality
Table 4 Results of the logistic regression analysis to predict “improved” participants
Independent variables b (SE) p 95% CI for Odds Ratio
Lower Odds Ratio Upper
Intercept −3.51 (1.25) 0.01
STarT Back Screening Tool score 0.43 (0.23) 0.07 0.97 1.53 2.41
Initial expectation: positive vs negative −1.53 (0.94) 0.11 0.03 0.22 1.37
Slope of the change in pain intensity across the four sessions 0.39 (0.14) 0.01* 1.13 1.48 1.94
Slope of the change in T6 tenderness across the four sessions 0.01 (0.01) 0.50 0.98 1.01 1.04
Slope of the change in T6 tenderness between the first two sessions 0.13 (0.07) 0.048* 1.00 1.14 1.29
Slope of the change in T7 tenderness between before-and-after the first SMT/rest 0.09 (0.15) 0.57 0.81 1.09 1.48
Slope of the change in T8 tenderness between the first two sessions 0.07 (0.05) 0.22 0.96 1.07 1.19
Slope of the change in T8 terminal spinal stiffness between the first two sessions −1.00 (0.71) 0.16 0.09 0.37 1.48
Note: A positive slope indicates an improvement. R2 = 0.36 (Cox & Snell), 0.53 (Nagelkerke). Model χ2(8) = 32.02, p < 0.001
* Statistically significant predictor/variable
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itself (see the discussion related to the variables associ-
ated with improvement).
Regarding the secondary outcomes, it remains difficult
to determine if the changes observed between the first
and the last sessions are clinically significant. Although
statistically significant, the change in tenderness during
spinal stiffness remains small and failed to reach the
MCID of 15%. The MCID for spinal stiffness is not
known but some hypothesis can be raised from the
current literature. Latimer et al. (1996) observed an 8%
decrease in the initial spinal stiffness when participants
reported an improvement of at least 80% in their LBP
intensity [34]. This percentage would have represented a
decrease of at least 0.60 N/mm in the current study,
which is twice the average decrease observed. On the
other hand, Wong et al. (2015) showed that, in partici-
pants with LBP, a clinical improvement in disability fol-
lowing two treatment sessions is associated to an
average decrease in L3 spinal stiffness of 0.26 N/mm
(95%CI = 0.08–0.43 N/mm), which is similar to the
changes observed in the current study [15]. Finally, in
contrast to the observation of an increase in spinal stiff-
ness in participants with LBP [35], a decrease in this par-
ameter has been observed in participants with chronic
thoracic pain [26]. It is therefore more likely that these
changes in spinal stiffness are not clinically relevant.
Variables associated with improvement
Considering that people with back pain constitutes a
heterogenous population, an exploratory analysis was
conducted to identify potential factors associated with a
moderate to strong improvement at follow-up. Interest-
ingly, 65% of the 18 “improved” participants received
high peak force doses, suggesting that higher peak force
increases the probability of improvement in at least
some individuals. Current biomechanical and neuro-
physiological models mostly explained SMT clinical ef-
fects by the stimulation of spinal reflexes resulting,
among others, in a hypoalgesia effect [36], an increase in
spinal mobility [37] and an increase in maximum volun-
tary contraction and proprioception [38]. However, it
cannot be excluded that these clinical effects have, at
least partly, been mediated by other factors such as the
ones related to the context of treatment [39]. Previous
studies showed that participants with neck pain receiv-
ing SMT and initially believing that this therapy would
help them were more likely to improve in comparison to
participants not considering this therapy as potentially
beneficial [29, 40]. In the current study, 90.5% of partici-
pants initially presenting a negative expectation towards
the treatment effect were, indeed, “not improved” at the
fourth session. Noteworthy, participants with negative
expectations were twice as many in the control and low
peak force dose groups than in the high peak force dose
groups. The portion of the clinical improvement associ-
ated with these nonspecific effects is not known, but
these results highlight the importance of considering pa-
tient preferences and expectations in the choice of treat-
ment modalities. Interestingly, previous studies failed to
identify a prognostic value for the STarT Back Screening
Tool in chiropractic settings [41]. In contrast to the
studies included in the narrative review of Khan (2017),
the 0–9 score was used in the current study instead of
the 3-level risk stratification suggested by Hill et al.
(2008) [42]. A score of > 3/9 on the SBST suggests the
presence of physical findings that needs to be tailored,
which can be accompanied or not by psycho-social bar-
riers to recovery [42]. The reason why individuals with
higher SBST score were more likely to be “improved” is
not known but such results certainly warrants further
investigation. The exploratory analysis also supports pre-
vious literature on the importance of response to first
treatments [43, 44]. Indeed, a greater slope of change in
pain intensity across the four sessions and a greater
slope of change in tenderness during spinal stiffness at
the targeted vertebra were predictors of a moderate to
strong improvement. Considering that patients’ im-
provement at the fourth session was shown to be a
strong predictor of patient improvement at 3 and 12
months [45], importance of monitoring patient changes
in pain intensity and tenderness across the first treat-
ments to determine if a specific management is appro-
priate needs to be investigated.
Neuromechanical responses and SMT
The current results do not support the hypothesis that SMT
characteristics influence the clinical effects of this therapy.
Indeed, the comparisons of the neuromechanical responses
between the three experimental groups confirmed that dif-
ferent responses were triggered although no between-group
differences were revealed. Greater absolute vertebral dis-
placement (indirectly obtained by the indenter displace-
ment) was recorded in the two high peak force doses
compared to the low peak force dose. Relative displacements
were not measured in the current study, but SMT of lower
peak force would unavoidably result in a lower relative dis-
placement compared to SMT of greater peak force when de-
livered with a similar rate of force application. Although it
was initially hypothesized that the two high rate of force ap-
plication doses would show similar and greater muscle re-
sponse than the low rate dose, the only significant difference
was observed between the high peak force/high rate dose
and the low peak force/low rate dose. Whether a certain
threshold of either neuromechanical responses is required
to produce a clinical effect in participants with back pain
can’t be determined with the design of the current study but
should be considered in future studies.
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Strengths and limitations
This study provides the first preliminary data regarding the
influence of SMT characteristics on the therapy clinical/bio-
mechanical effects using an RCT. The main strength is the
between-group comparisons using a randomization sequence
to minimize differences between them. Unfortunately, des-
pite randomization, between-group differences in baseline
pain intensity were present which may have influenced the
results. Moreover, this study used a mechanical device to de-
liver SMT and to assess spinal stiffness, which minimized
between-participants and between-day variations. In contrast
to previous studies evaluating SMT clinical effects, the ther-
apy characteristics and the size of the contact surface were
controlled in the current study. Moreover, a low attrition rate
was reached (i.e. 7%).
Some limitations also need to be considered when
interpreting the results of the current study. First, the in-
terventions were not delivered within a clinical setting;
therefore, the effects related to the clinician-patient rela-
tionship, the SMT modulation during its delivery through
feedback mechanisms, and to other components of patient
management have not been evaluated. This constitute
both a strength and a limitation of the study since it
allowed the evaluation of the effect related to the SMT it-
self but did not capture the whole effect of a management
involving this therapeutic modality. Secondly, in average,
participants initially presented levels of pain intensity and
disability that can be considered as being low to moderate.
Results should therefore should be generalized with cau-
tion to other populations and future studies should recruit
participants with a more clinically relevant status. It must
also be noted that only three doses were evaluated. These
doses, selected based on the previously conducted studies
with the same apparatus [8–11], do not represent the
whole and neither the average range of values performed
by clinicians. Moreover, to ensure safety, peak forces
remained in the lower/mid-range of forces reported in the
literature which imply lower dose than the ones that could
be delivered to certain patients within a clinical setting
(e.g. for a large or fit [wo]man). It is consequently relevant
to conduct studies comparing other doses or evaluating
associations between SMT characteristics performed by
clinicians and the clinical improvement of patients. Fi-
nally, considering that the therapy characteristics and the
treated area were not tailored to the participant’s morph-
ology and complaints, future studies should investigate
whether a personalized/targeted treatment can optimize
clinical effects as well as if a participant not improving fol-
lowing a SMT dose could improve with a different one.
Conclusion
This study showed, that in an experimental setting, the
delivery of a SMT does not lead to significantly different
outcomes (clinical and biomechanical) in participants
with chronic thoracic pain than a control condition only
including the evaluation of spinal stiffness. A decrease in
pain intensity, disability, spinal stiffness and tenderness
during spinal stiffness assessment following four experi-
mental sessions was observed regardless of the group al-
location. Studies are still required to explore the
mechanisms underlying SMT clinical effects and to iden-
tify key characteristics of patients rapidly improving with
this therapeutic modality. Overall, the observation of a
rapid decrease in pain intensity and in tenderness during
pressures over the spinous processes are performed con-
stitute a better indicator of treatment success than the
treatment characteristics.
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